Compare Mesoblast Limited (MESO) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs NetApp Inc. — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while NetApp Inc. trades at $164.19 (market cap $31.57B). The key difference: NetApp Inc. is far larger — about 14.5× Mesoblast Limited's market cap, and NetApp Inc. pays a 1.29% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | NTAP | |
|---|---|---|
Market Cap | $2.17B | $31.57B |
Sector | Technology | Technology |
52-Week High | $20.96 | $181.08 |
52-Week Low | $12.88 | $94.11 |
Enterprise Value | $2.17B | $30.72B |
Dividend Yield | — | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
NetApp (NTAP) trades at $161.16, down 1.66% on the day, near its pivot point of $164. The stock exhibits a bullish technical trend with strong moving average signals. Fundamentally, the company shows robust profitability with a net income margin of 18.43% and has beaten earnings estimates for three consecutive quarters. Recent strategic moves include the acquisition of DataPelago to bolster AI data infrastructure capabilities, signaling growth focus.
The outlook for NTAP is positive, driven by AI-driven demand and consistent earnings outperformance, though risks include competitive pressures and reliance on enterprise spending. Analyst consensus leans bullish with a price target of $167.45, offering modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
